Weekly Recap | LEADS BIOLABS-B -6.79%, most brokers rate it buyWeekly Review·Nov 14, 2026 at 05:48 AM09887-2.74%
Weekly Recap | LEADS BIOLABS-B +3.8%, most brokers rate it buyWeekly Review·Nov 7, 2026 at 09:37 AM09887-2.74%
Leads Biolabs Doses First Patient with Systemic Lupus Erythematosus in Phase I Part B Trial of LBL-047, a First-in-Class BDCA2/TACI Bifunctional Fusion ProteinMorningStar·Oct 30, 2026 at 06:18 AM09887-2.74%
CLSA: Recent Pullback in China Healthcare Sector a Buying Opportunity as Overseas and Domestic Trends ImproveAASTOCKS News·Oct 28, 2026 at 06:33 AM01093+3.82%01801+1.74%
Nanjing Leads Biolabs Reports 8.7-Month Median Survival With LBL-024 in Late-Line EP-NEC TrialPUBT·Oct 26, 2026 at 09:51 AM09887-2.74%